The burden of disease during seasonal influenza epidemics is felt most keenly among the very young and the elderly. Although vaccination effectively protects children and young adults against infection, it has limited efficacy in elderly individuals. This has been linked to a reduced ability to induce a robust serum antibody response. In this issue of the JCI, Sasaki et al. identify some of the cellular and molecular deficits that underlie the reduced serum antibody response induced by influenza vaccination in elderly individuals. Importantly, they show that it is the quantity of the response, and not its quality, that needs to be improved if we are to enhance the success of influenza vaccination in this vulnerable population.
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The authors have declared that no conflict of interest exists. Vaccination against influenza has been described to be effective in preventing infection in healthy children and young adults; however, many of the elderly individuals who receive the vaccine still contract the infection and have secondary complications that lead to hospitalization and/or disability (2, 3) . Despite this, influenza vaccination is still universally recommended for elderly individuals, because it does reduce disease severity, but understanding the mechanism(s) that underlies the limited response of the elderly to influenza vaccines could help direct the development of more effective approaches.
Influenza infection and vaccination
Antibodies play a key role in protecting against infection with the influenza virus, and these are induced upon vaccination with current influenza vaccines, especially in healthy adults (4, 5) . Vaccination induces a population of circulating antibody-secreting cells (ASCs; also known as plasmablasts), defined as CD19 + CD20 lo/-CD3 -CD38 hi CD27 hi cells, which are detected with a peak around seven days after vaccination (6, 7 There is substantial evidence that the antibody response induced by influenza vaccines decreases with age (9-11). Most of the studies conducted so far have shown that this correlates with the well-characterized age-dependent decrease in T cell functions (12) (13) (14) . However, immune defects with age do not occur in T cells alone. Recently, agerelated autonomous B cell defects have been described (15, 16) . These include decreased class switch recombination (CSR), the process by which activated B cells change the isotype of the antibody that they are producing so that antibodies with the same specificity but different effector function can participate in the immune response; decreased expression of components of the molecular pathway controlling CSR, which include the enzyme activation-induced cytidine deaminase and the transcription factor E47; and decreased levels of switch memory B cells (15, 16) . These changes completely correlate with the reduced antibody response of elderly individuals to the influenza vaccine (17), and we suggest that they could be used as biomarkers to predict immune/vaccine responsiveness.
Despite agreement that the limited efficacy of vaccination against influenza in the elderly is linked to reduced serum antibody responses, it is not clear whether this is due to decreases in the quantity and/or the quality of the antibodies produced. If it is the quantity, is it due to a decrease in the number of ASCs or in the amount of antibody secreted per cell? The quantity of the serum antibody response is determined by the number of plasmablasts and the amount of antibody secreted by each plasmablast, whereas the quality, or avidity, depends on the affinity of the Igs produced for their cognate antigen. A paper in this issue of the JCI by Sasaki and collaborators addresses these key questions (18) . The paper confirms previous studies showing that the serum response, evaluated as fold increase in titer after vaccination, is reduced in elderly individuals and, importantly, extends these findings to show that the number of responding plasmablasts and hence plasmablast-derived polyclonal antibodies (PPAbs) is dramatically reduced in elderly individuals compared with that in young individuals (Figure 1 ). In addition to answering the questions above, Sasaki et al. have efficiently used a system, previously established by Wilson, Ahmed, and colleagues (6, 7) , to assay the quality of antibodies secreted from single cells in elderly individuals compared with that in young individuals.
Decreased quantity of plasmablasts contributes to decreased elderly vaccine response
The system used by Sasaki and colleagues to analyze the antibody response to vaccination against influenza (18) enables researchers to measure primarily new antigen-specific antibody responses or those generated by switch memory B cells by focusing on plasmablasts, which peak at day 7 after exposure to a new antigen, in the case of Sasaki et al., the inactivated seasonal influenza vaccine. The plasmablasts are isolated and analyzed in bulk to assess the vaccine-specific PPAb response or, as single cells (clones), to analyze the specific Ig sequences expressed by each cell and the affinity of the mAb each cell produces. The ability to measure the vaccine-specific antibody response provides a way to avoid measuring preexisting cross-reacting serum antibody specificities generated by previous vaccinations. The system used by Sasaki
Figure 1
Mechanistic explanation for the inferior antibody response to influenza vaccination in the elderly. The efficacy of influenza vaccination wanes with age. This is linked to a reduced ability to induce a robust serum antibody response. However, whether it is due to decreases in the quantity and/or the quality of the antibodies produced is not clear. In this issue of the JCI, Sasaki et al. answer this question (18) , showing that the reduced serum antibody response generated by the elderly after vaccination with inactivated seasonal influenza vaccine is a result of a decrease in the number of responding plasmablasts and hence a decrease in the concentration of PPAbs, rather than a result of a decrease in the quality of the response. Importantly, the amount of antibody secreted was about the same for individual plasmablasts isolated from (A) young and (B) elderly individuals.
and collaborators (18) therefore enabled them to focus on whether each vaccinated individual had the ability to generate a new beneficial antibody response or not.
Using this approach, Sasaki and colleagues were able to demonstrate that not only is the number of vaccine-specific plasmablasts decreased in elderly individuals, as compared with that in healthy young adults, but that the concentration of PPAbs is also decreased (Figure 1 and ref. 18) . Conversely, the avidity of these vaccine-specific antibodies and the affinity of recombinant mAbs obtained from single cell plasmablasts were similar in the two age groups. These results support the conclusion that the lower efficacy of the influenza vaccine in the elderly is due to a quantitative difference in the number of antibody-secreting plasmablasts.
The results from Sasaki et al. (18) clearly show that the frequency of vaccine-specific plasmablasts circulating one week after vaccination is lower in elderly individuals as compared with that in young individuals. The age-dependent defect in CSR (15, 16) (discussed earlier in Influenza infection and vaccination) leads to reduced amounts of not only IgG antibodies but also switch memory B cells (17) , and this could be part of the mechanism by which vaccine-specific plasmablast numbers wane with age. The lower plasmablast response observed by Sasaki et al. in the elderly (18) may also be due to impaired reactivation of memory B cells and/ or diminished activation of naive B cells, the cell numbers of which have both been shown to be reduced in the elderly (16, 17, 19, 20) . The vaccine-specific plasmablasts characterized by Sasaki et al. are generated in vivo, and the defect seen could also reflect deficits of age in various immune cell types other than B cells, including T cells and dendritic cells.
The work of Sasaki and collaborators shows that the amount of vaccine-specific PPAb (both IgG and IgA) secreted by bulk plasmablast cultures was decreased in elderly individuals compared with that in young individuals (18) . Further, in both age groups, the amount of vaccine-specific IgG produced was statistically higher than the amount of vaccine-specific IgA. Importantly, the amount of antibody secreted by individual plasmablasts was about the same for cells isolated from both elderly and young individuals. Therefore, the primary defect in elderly individuals is in the number of plasmablasts induced by vaccination, rather than in the amount of antibody secreted per cell. Sasaki et al. also evaluated the avidity of vaccine-specific PPAbs in young and elderly individuals and found no statistically significant difference in the avidity of vaccine-specific IgG and IgA in the two age groups (18) . The variable regions of the Igs isolated from single sorted plasmablasts showed no significant affinity difference, at least in the limited number of young and elderly individuals. Therefore, Sasaki and collaborators conclude that the quality of the antibodies produced (both polyclonal and monoclonal) in young and elderly individuals after influenza vaccination is comparable (18) .
Looking toward the future
The work of Sasaki and colleagues (18) answers/addresses a major mechanistic question about what the defect in the response to vaccination against influenza is in elderly individuals. Importantly, it also offers a method to be able to measure and perhaps predict the quality of the vaccine-induced antibody response in all individuals vaccinated against influenza - simply analyze the frequency of the peripheral vaccine-specific plasmablast response. A decreased plasmablast response for one vaccine is likely to correlate with the response to subsequent vaccinations and so would help predict the general immune capability of the individual. It is and will be important to accurately monitor as well as predict, via the generation of accurate biomarkers, immune responses that correlate with effective disease prevention, and the work of Sasaki et al. (18) adds an important biomarker for this goal. The development of accurate biomarkers will help determine in which patients altered/enhanced vaccines should be used and beckons us to generate not only better adjuvants but also to screen for pharmaceutical and/or lifestyle changes that can improve vaccine responses to ensure effective disease prevention.
